31 July 2021>: Clinical Research
Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy
Xingqin Zhou 1BCE , Yazhou Chang 2BD , Jing Qian 1BF , Chaoyan Shen 1DEF , Jie Han 1EF , Hongyu Zhao 1DF , Renan Chang 3AG*DOI: 10.12659/MSM.929474
Med Sci Monit 2021; 27:e929474
Figure 1 Distribution of measured 5-FU exposure (AUC) in every cycle of the Study Group. The AUC mean of the third cycle was significantly increased compared to the one at the first cycle (P=0.006).